• Effect of Estradiol Pretreatment on Antagonist ICSI Cycles

  NCT05197374

  CompletedInterventionalPhase 4Updated Feb 3, 2022
• Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)

  NCT00823472

  TerminatedInterventionalPhase 4Updated Jan 29, 2019
• Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days

  NCT01468441

  CompletedInterventionalNot ApplicableUpdated Jul 13, 2012
• Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

  NCT04724343

  CompletedInterventionalPhase 4Updated Oct 24, 2023
• Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

  NCT00417183

  Unknown statusInterventionalPhase 4Updated Dec 29, 2006
• Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

  NCT00883766

  TerminatedInterventionalNot ApplicableUpdated Jul 20, 2012

ClinicalTrials.gov ID

NCT06879002

Lead Sponsor

ART Fertility Clinics LLCOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

252Estimated

Last Update Posted

May 7, 2026Actual

Start Date

Dec 30, 2026Estimated

Primary Completion Date

Apr 30, 2027Estimated

Completion Date

Dec 30, 2027Estimated

Official Title

To Compare IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Fixed Day 5 Antagonist Protocol

Brief Summary

There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.

• Stimulation in the Ovary
• IVF Outcome

• Ovarian stimulation with menstruation or after ovulation

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Age 18 to 38 years old.
• Normal Menstrual cycle of 25-35 days.
• Body Weight 60to90 kg
• AMH>1.3 - <3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of >5 on menstrual cycle days 2-3,

Exclusion Criteria:

• History of premature ovulation
• Azoospermia
• PCOS
• Endometriosis AFS ¾
• Endometrioma
• Known chromosomal abnormalities

Observational Model

Case-Only

Time Perspective

Prospective

Lead Sponsor

ART Fertility Clinics LLCOTHER

jonalyn.edades@artfertilityclinics.com+97126528000